Qritive, a leading provider of AI solutions for pathology labs globally, has announced strategic partnerships with three distinguished diagnostic centers and hospitals in India: Metropolis Healthcare, Rajiv Gandhi Cancer Institute, and CŌRE Diagnostics. These institutions have embraced Qritive’s PantheonTM image management system (IMS) and AI products, marking a groundbreaking step in integrating artificial intelligence into pathology workflows.
The adoption of Qritive’s AI technology by these prestigious healthcare institutions represents a significant advancement in modernizing pathology practices. By leveraging AI, they aim to enhance diagnostic accuracy, improve operational efficiency, and ultimately elevate patient care standards.
Metropolis Healthcare CEO, Mr. Surendran Chemmenkottil, expressed enthusiasm about the transformative potential of Qritive’s AI platform, emphasizing its revolutionary impact on precision, timeliness, and personalized diagnosis, particularly in prostate cancer detection.
Bruno Occhipinti, CEO of Qritive, highlighted the collaboration with forward-looking healthcare institutions and emphasized how AI can support clinicians, contributing to the objectives of World Cancer Day on February 4th.
CŌRE Diagnostics CEO, Mr. Dinesh Chauhan, emphasized the collaboration’s potential to enhance diagnostic precision, improve patient outcomes, and potentially lead to the development of new AI services for rare disease diagnosis.
Qritive’s AI-powered platform has demonstrated substantial improvements in pathology workflows, with clinical studies indicating up to a 90% reduction in diagnosis time and an 80% decrease in discordance among pathologists. Such enhancements translate to increased diagnostic accuracy and an overall improvement in cancer patient care quality.
Dr. Gurudutt Gupta, HOD Pathology at Rajiv Gandhi Cancer Institute Research Centre, praised the benefits of Qritive’s IMS and AI modules in enhancing workflow and diagnostic precision.
Qritive, headquartered in Singapore with operations in the US and India, focuses on AI solutions for cancer diagnosis, utilizing deep learning technology to support pathology test interpretation.
About Metropolis Healthcare Limited, established in 1981, it is a leading diagnostics company in India and internationally, providing a comprehensive range of tests and profiles. Metropolis is committed to quality, technological superiority, and a patient-centric approach.
CŌRE Diagnostics, a CAP and NABL Accredited laboratory chain, specializes in high-end diagnostics in India and internationally. It offers comprehensive testing in areas like oncology, neurology, reproductive medicine, and rare diseases.
Rajiv Gandhi Cancer Institute and Research Centre, based in Delhi, is a non-profit medical facility specializing in cancer treatment and research, ranking among the largest cancer treatment centers in Asia.